West Europe
Germany· KamenBioNTech Halts Cancer Drug Development, Stock Drops
BioNTech, a German pharmaceutical company, has stopped the development of one of its cancer medications, leading to a 10% drop in its stock value.
Quorum · collective opinions
BioNTech Halts Development of Cancer Drug, Stock Drops
First report 5h agoLast update 5h ago1 takes 1
report drug development haltneutralShow 1 post
started 5h ago•Last update 5h ago
BioNTech's decision to discontinue a cancer drug development program has resulted in a significant decline in its stock price.
iWitness comments
No comments yet — be the first to weigh in.